OrsoBio
G. Mani Subramanian currently serves as the CEO of OrsoBio, a position held since April 2020. Prior to this role, G. Mani Subramanian was the Senior Vice President and Liver Diseases TA Head at Gilead Sciences from January 2011 to March 2020. Previous experience includes serving as Executive Director of Clinical Research in Infectious Diseases and Immunology at Human Genome Sciences from July 2002 to December 2010, and as Senior Staff Scientist at Celera Corporation from March 2000 to July 2002. G. Mani Subramanian's educational background includes a fellowship in Infectious Diseases at the National Institute of Allergy and Infectious Diseases, an internal medicine residency at the University Hospitals of Cleveland, a PhD in Microbiology and Immunology from the University of Michigan Medical School, and an MD from Armed Force Medical College, Pune.
This person is not in any teams
OrsoBio
OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.